摘要
以１３１Ⅰ标记肝癌单克隆抗体ＨＡｂ２５，观察其在肝癌患者体内的免疫定位作用及其血药动力学．５例原发性肝癌患者，经静脉平均注入１４８ＭＢｇ／１ｍｇ的１３１Ⅰ－ＨＡｂ２５，动态观察显示：定位显像４例为阳性，最佳时间为给药后７２ｈ，癌／肝比值第４８ｈ为２．０５±０．４２，第７２ｈ为３．７３±０．３４，第９６ｈ为２．７５±０．７２；１３１Ⅰ—ＨＡｂ２５的血清Ｔ１／２ａ为２６．２ｈ，Ｔ１／２Ｂ为４３．６ｈ，循环血液中的放射性主要存在于血浆中，静脉给药后２８ｈ内约有给予放射性总剂量的５０％由尿排出．本研究提示：ＨＡｂ２５在体内可特异性定位于肝癌组织，１３１Ⅰ－ＨＡｂ２５结合物在体内不稳定，有明显的脱碘现象。
The targeting location and pharmacokinetics of 131labeled HAb25 McAb against primaryhepatocelluler(PHC)carcinoma were investigated in human body. Five patientS with PHC wereadministrated i.v.with a mean dosage of 148 MBq/ling 131I-HAb25. Dynamic observations showedthat four of the PatientS had POsitve scans(80%)and the optimum imaging time was 72 hours afteradministration.The mean tumor/liver ratioes were 2.051 0.42,3.73±0.34 and 2.75±0.72 after 48,72and 96 hours of i.v.administration of the labeled McAb.Blood radioactivities were associatedpredominantly with plasma rather than cellular elements.The urinary excretion of radioactivity wasabout 50% of the injected dosage in the first 28 hours.These resultS revealed that HAb25 McAb wasable to target to PHC tissues in human body and the 131I-HAb25 conjugate was unstablhed bydeiodination in vivo.
关键词
肝肿瘤
单克隆抗体
导向疗法
药代动力学
primary carcinoma
antibody,monoclonal
targeting
location
pharmacokinetics
